Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CS-101 in Beta-Thalassemia: NCT07489196 Clinical Landscape Report 2026
11 September 2026
NCT07489196 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lisaftoclax in Acute Myeloid Leukemia: NCT07813390 Clinical Landscape Report 2026
11 September 2026
NCT07813390 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zeleciment Rostudirsen in Duchenne and Becker Muscular Dystrophy: NCT07608432 Clinical Landscape Report 2026
11 September 2026
NCT07608432 clinical landscape for Duchenne and Becker Muscular Dystrophy: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Florbetaben F-18 in Alzheimer Disease: NCT07787169 Clinical Landscape Report 2026
11 September 2026
NCT07787169 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
8 min read
Autologous human adipose tissue derived bone tissue therapy (Bonus BioGroup) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Autologous human adipose tissue derived bone tissue therapy (Bonus BioGroup): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
Anti-CD19 CAR-T (The Children's Hospital of Philadelphia) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Anti-CD19 CAR-T (The Children's Hospital of Philadelphia): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development.
8 min read
SPX-303 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
SPX-303: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
CHF-6333 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
CHF-6333: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
B-901 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
B-901: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
HY-0102 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
HY-0102: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
VGN-R08 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
VGN-R08: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Oncolytic vaccinia virus (Huayao Kangming) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Oncolytic vaccinia virus (Huayao Kangming): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing.